Indications for: SPEVIGO

Generalized pustular psoriasis (GPP) flares.

Adult Dosage:

900mg as a single dose by IV infusion over 90mins. May give additional 900mg dose after 1 week if flare symptoms persist. 

Children Dosage:

Not established.

SPEVIGO Warnings/Precautions:

Increased risk of infections. Consider risks/benefits prior to initiating if chronic or history of recurrent infection. Latent or history of TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Patients with active TB infection: do not initiate. Monitor for active TB during and after therapy. Discontinue immediately if anaphylaxis or other serious hypersensitivity develops (eg, DRESS). Interrupt and consider appropriate treatment if mild or moderate infusion-related reactions develop. Pregnancy. Nursing mothers. 

SPEVIGO Classification:

Interleukin-36 receptor antagonist.

SPEVIGO Interactions:

Avoid concomitant live vaccines. 

Adverse Reactions:

Asthenia, fatigue, nausea, vomiting, headache, pruritus, prurigo, infusion site hematoma, bruising, urinary tract infection; DRESS. 



Drug Elimination:

Half-life: 25.5 days. 

Generic Drug Availability:


How Supplied:

Single-dose vials—2